Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| adipocyte | 10 studies | 64% ± 19% | |
| microglial cell | 8 studies | 26% ± 10% | |
| type I pneumocyte | 7 studies | 26% ± 7% | |
| plasmacytoid dendritic cell | 6 studies | 24% ± 9% | |
| endothelial cell | 5 studies | 24% ± 9% | |
| cardiac muscle cell | 5 studies | 48% ± 12% | |
| glutamatergic neuron | 5 studies | 41% ± 21% | |
| GABAergic neuron | 4 studies | 40% ± 16% | |
| astrocyte | 4 studies | 21% ± 6% | |
| CD4-positive, alpha-beta T cell | 4 studies | 24% ± 6% | |
| T cell | 4 studies | 22% ± 4% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| regulatory T cell | 3 studies | 18% ± 3% | |
| oligodendrocyte precursor cell | 3 studies | 20% ± 4% | |
| dendritic cell | 3 studies | 21% ± 3% | |
| macrophage | 3 studies | 22% ± 2% | |
| type II pneumocyte | 3 studies | 20% ± 3% | |
| fibroblast | 3 studies | 19% ± 5% | |
| lymphocyte | 3 studies | 19% ± 4% | |
| interneuron | 3 studies | 40% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| skin | 100% | 1346.11 | 1806 / 1809 | 99% | 6.05 | 469 / 472 |
| intestine | 100% | 1158.24 | 963 / 966 | 99% | 6.86 | 521 / 527 |
| lung | 99% | 1259.45 | 575 / 578 | 99% | 4.51 | 1140 / 1155 |
| breast | 99% | 3085.26 | 455 / 459 | 99% | 4.08 | 1104 / 1118 |
| uterus | 98% | 836.31 | 167 / 170 | 94% | 3.21 | 430 / 459 |
| esophagus | 91% | 940.07 | 1320 / 1445 | 100% | 6.26 | 183 / 183 |
| thymus | 100% | 2343.94 | 653 / 653 | 91% | 3.15 | 550 / 605 |
| bladder | 95% | 1015.86 | 20 / 21 | 93% | 4.22 | 467 / 504 |
| stomach | 87% | 656.47 | 312 / 359 | 99% | 6.36 | 284 / 286 |
| adrenal gland | 100% | 1164.00 | 258 / 258 | 80% | 1.85 | 184 / 230 |
| prostate | 98% | 983.05 | 240 / 245 | 77% | 1.54 | 385 / 502 |
| kidney | 88% | 608.10 | 78 / 89 | 85% | 2.11 | 769 / 901 |
| brain | 52% | 358.31 | 1386 / 2642 | 98% | 2.98 | 690 / 705 |
| ovary | 48% | 261.22 | 86 / 180 | 85% | 2.22 | 367 / 430 |
| pancreas | 30% | 132.22 | 98 / 328 | 93% | 2.98 | 166 / 178 |
| adipose | 100% | 3698.01 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 8.31 | 29 / 29 |
| muscle | 100% | 5757.00 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1258.00 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.34 | 1 / 1 |
| blood vessel | 98% | 1021.98 | 1309 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 1572.53 | 836 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 2.74 | 41 / 45 |
| eye | 0% | 0 | 0 / 0 | 85% | 2.34 | 68 / 80 |
| peripheral blood | 59% | 787.32 | 552 / 929 | 0% | 0 | 0 / 0 |
| liver | 9% | 49.74 | 20 / 226 | 37% | 0.83 | 151 / 406 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1903826 | Biological process | L-arginine transmembrane transport |
| GO_0015804 | Biological process | neutral amino acid transport |
| GO_0031460 | Biological process | glycine betaine transport |
| GO_1903401 | Biological process | L-lysine transmembrane transport |
| GO_0015822 | Biological process | ornithine transport |
| GO_0006809 | Biological process | nitric oxide biosynthetic process |
| GO_0003333 | Biological process | amino acid transmembrane transport |
| GO_0015820 | Biological process | L-leucine transport |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0061459 | Molecular function | L-arginine transmembrane transporter activity |
| GO_0034618 | Molecular function | arginine binding |
| GO_0015171 | Molecular function | amino acid transmembrane transporter activity |
| GO_0015179 | Molecular function | L-amino acid transmembrane transporter activity |
| GO_0106439 | Molecular function | L-lysine:L-arginine antiporter activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0015174 | Molecular function | basic amino acid transmembrane transporter activity |
| Gene name | SLC7A6 |
| Protein name | Y+L amino acid transporter 2 (Cationic amino acid transporter, y+ system) (Solute carrier family 7 member 6) (y(+)L-type amino acid transporter 2) (Y+LAT2) (y+LAT-2) Y+L amino acid transporter 2 (Solute carrier family 7 member 6) (y(+)L-type amino acid transporter 2) Solute carrier family 7 member 6 |
| Synonyms | KIAA0245 |
| Description | FUNCTION: Heterodimer with SLC3A2, that functions as an antiporter which operates as an efflux route by exporting cationic amino acids such as L-arginine from inside the cells in exchange with neutral amino acids like L-leucine, L-glutamine and isoleucine, plus sodium ions and may participate in nitric oxide synthesis . Also exchanges L-arginine with L-lysine in a sodium-independent manner . The transport mechanism is electroneutral and operates with a stoichiometry of 1:1 . Contributes to ammonia-induced increase of L-arginine uptake in cerebral cortical astrocytes leading to ammonia-dependent increase of nitric oxide (NO) production via inducible nitric oxide synthase (iNOS) induction, and protein nitration (By similarity). May mediate transport of ornithine in retinal pigment epithelial (RPE) cells . May also transport glycine betaine in a sodium dependent manner from the cumulus granulosa into the enclosed oocyte (By similarity). . |
| Accessions | ENST00000219343.11 H3BRZ8 ENST00000566454.5 H3BPK5 ENST00000563146.1 ENST00000563080.1 ENST00000568088.5 H3BNF5 H3BUA4 J3QL60 ENST00000562727.1 Q92536 A0AUM0 ENST00000566579.5 H3BSB6 H3BPV6 ENST00000564708.1 H3BSV7 ENST00000648130.1 ENST00000566834.5 ENST00000618043.4 E7EPZ8 ENST00000379152.7 ENST00000568024.1 ENST00000567346.5 H3BUR2 |